Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.57 |
| ▸ | AVPR1B | P47901 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1140548 | 0.94 | MAPK14 (0.61) | MAPK14AVPR1B | |
| SCHEMBL1140580 | 0.94 | MAPK14 (0.61) | MAPK14AVPR1B | |
| SCHEMBL1140587 | 0.93 | MAPK14 (0.64) | MAPK14AVPR1B | |
| Hydrochloric Acid SCHEMBL1140377 | 0.92 | MAPK14 (0.64) | MAPK14AVPR1B | |
| SCHEMBL1140402 | 0.92 | MAPK14 (0.65) | MAPK14AVPR1B | |
| SCHEMBL1140310 | 0.91 | MAPK14 (0.65) | MAPK14AVPR1B | |
| SCHEMBL1140057 | 0.89 | MAPK14 (0.64) | MAPK14AVPR1B | |
| SCHEMBL1140458 | 0.89 | MAPK14 (0.64) | MAPK14AVPR1B | |
| SCHEMBL1140718 | 0.86 | MAPK14 (0.64) | MAPK14 | |
| SCHEMBL1140062 | 0.86 | MAPK14 (0.59) | MAPK14AVPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1682520-B1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-02-23 | — | — | EP | disclosed |
| US-7750154-B2 | Amide derivatives | ASTRAZENECA AB (SE) | 2010-07-06 | — | — | US | disclosed |
| US-20070043065-A1 | Amide derivatives | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043065-A1 | Amide derivatives | IL6, IL2, IL1B | MAPK14 2518/4885AVPR1B 533/4885TP53 1824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.